Calcium Channel Blockers- Induced Iatrogenic Gingival Hyperplasia: Case Series

被引:0
作者
Priyadarshini, G. Agnes Golda [1 ]
Edsor, Effie [2 ]
Sajesh, S. [2 ]
Neha, K. [1 ]
Gangadhar, Reneega [1 ]
机构
[1] Sree Mookambika Inst Med Sci, Dept Pharmacol, Kanyakumari, Tamil Nadu, India
[2] Sree Mookambika Inst Med Sci, Dept Oral & Maxillofacial Surg, Kanyakumari, Tamil Nadu, India
关键词
Calcium channel blockers; gingival hyperplasia; hypertension; MANAGEMENT;
D O I
10.4103/jpbs.jpbs_634_22
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hypertension rightfully termed as "Silent killer" is associated with increase in morbidity and mortality when left untreated. Calcium channel blockers are the most commonly prescribed first-line anti-hypertensive drugs in India. Calcium channel blockers are known to cause gingival hyperplasia but with lower incidence rates compared to the other two groups causing iatrogenic gingival overgrowth, immunosuppressants, and anticonvulsants. Nifedipine administration, among the calcium channel blockers, has been frequently associated with iatrogenic gingival hyperplasia. Incidence of amlodipine-induced gingival hyperplasia which has similar pharmacodynamic action like nifedipine, had been reported rarely. Here, we present a case series of drug induced gingival overgrowth caused by calcium channel blockers used for the management of hypertension. All the patient's condition improved after withdrawal of the offending drug, oral prophylaxis and intervention, and alternate drug from other first-line drugs were started for managing hypertension.
引用
收藏
页码:S821 / S824
页数:4
相关论文
共 20 条
  • [1] [Anonymous], 2021, Guideline for the pharmacological treatment of hypertension in adults. Web Annex A. Summary of evidence
  • [2] Management of periodontal disease in patients using calcium channel blockers - gingival overgrowth, prescribed medications, treatment responses and added treatment costs
    Fardal, Oystein
    Lygre, Henning
    [J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 2015, 42 (07) : 640 - 646
  • [3] Gopal Saumiya, 2015, J Indian Soc Periodontol, V19, P308, DOI 10.4103/0972-124X.153483
  • [4] Hall EE, 1997, CURR OPIN PERIODONT, V4, P59
  • [5] Hegde R., 2012, J Oral Health Comm Dent, V6, P34
  • [6] A Review of the JNC 8 Blood Pressure Guideline
    Hernandez-Vila, Eduardo
    [J]. TEXAS HEART INSTITUTE JOURNAL, 2015, 42 (03) : 226 - 228
  • [7] Drug-induced gingival hyperplasia: An in vitro study using amlodipine and human gingival fibroblasts
    Lauritano, Dorina
    Martinelli, Marcella
    Baj, Alessandro
    Beltramini, Giada
    Candotto, Valentina
    Ruggiero, Francesco
    Palmieri, Annalisa
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2019, 33
  • [8] GINGIVAL HYPERPLASIA ASSOCIATED WITH NIFEDIPINE THERAPY
    LEDERMAN, D
    LUMERMAN, H
    REUBEN, S
    FREEDMAN, PD
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1984, 57 (06): : 620 - 622
  • [9] Is fibroblast heterogeneity relevant to the health, diseases, and treatments of periodontal tissues?
    Lekic, PC
    Pender, N
    McCulloch, CAG
    [J]. CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1997, 8 (03) : 253 - 268
  • [10] The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth
    Mavrogiannis, M.
    Ellis, J. S.
    Seymour, R. A.
    Thomason, J. M.
    [J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 2006, 33 (09) : 677 - 682